GlassScriptPhysician profile
Steven Bojarski
NPI 1760412852
$1,226.65
in general payments reported to CMS, 2019-2025
23 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2021: $35.09 · 2022: $161 · 2023: $201 · 2024: $409 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $252.30 | 2023-2025 | Zeposia |
| Eisai INC. | $150.80 | 2024 | |
| Abbvie INC. | $142.11 | 2022-2025 | Qulipta, Ubrelvy |
| Genentech USA, INC. | $113.86 | 2019 | |
| Pfizer INC. | $70.51 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $55.26 | 2023-2024 | Xywav |
| Lundbeck LLC | $48.81 | 2024-2025 | Vyepti |
| Sunovion Pharmaceuticals INC. | $46.78 | 2022 | |
| Tactile Systems Technology INC | $42.88 | 2025 | Nimbl, Flexitouch Plus |
| Biohaven Pharmaceutical Holding Company LTD. | $41.96 | 2022 | |
| Argenx US, INC. | $36.39 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $29.08 | 2024-2025 | Kisunla, Amyvid |
| Amgen INC. | $25.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.00 | 2025 | Hyqvia |
| Biohaven Pharmaceuticals, INC. | $19.39 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $19.25 | 2022 | |
| Orthogenrx INC. | $18.51 | 2019 | |
| Ucb, INC. | $17.15 | 2025 | Rystiggo |
| Shield Therapeutics INC | $17.08 | 2023 | Accrufer |
| Neurelis, INC. | $15.70 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.31 | 2019 | |
| Emd Serono, INC. | $13.93 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.83 | 2024 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bojarski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.